|
Collaborations
Strategic alliances are central to Biosite Discovery. Its network of partnerships is continuously expanding and includes leading pharmaceutical and biotechnology firms as well as highly regarded academic and research institutions, such as Duke University, the Thrombolysis In Myocardial Infarction (TIMI) Group of Brigham and Women’s Hospital, Johns Hopkins University and the San Diego Veterans Administration Medical Center.
Alliances
Aug. 23, 2006
Biosite and Hopitaux Universitaires de Geneve Announce Kidney Injury Collaboration
Apr. 4, 2006
Biosite and Oxford Genome Sciences Announce Collaboration in Colorectal Cancer
Mar. 20, 2006
Lilly and Biosite to Collaborate on Clinical Trial Using Tailored Xigris Therapy
Feb. 21, 2006
Biosite and FivePrime Announce Antibody Collaboration
Aug. 25, 2005
SIRS-Lab and Biosite Announce Collaboration to Develop Diagnostics for Sepsis
Aug. 22, 2005
Biosite Announces Exclusive License for Cardiovascular Marker
Aug. 1, 2005
Biosite Announces Collaboration for Cerebrovascular Injury Targets
Jul. 13, 2005
Biosite Announces Exclusive License for Novel Renal Injury Marker
Jul. 12, 2005
Power3 Medical and Biosite Announce Diagnostic Collaboration
Feb. 7, 2005
Biosite Announces License Agreement for Novel Diagnostic Targets
Mar. 4, 2004
Biosite Signs Discovery Collaboration with DMI Biosciences for Cysteinylated Albumin (Cys-Albumin), a Biomarker That is Elevated in Blood When a Patient is Undergoing Ischemia
Feb. 25, 2004
Biosite Licenses Myeloperoxidase (MPO), a Significant Marker for Heart Disease from the Cleveland Clinic
Feb. 2, 2004
Biosite Signs Discovery Collaboration with Amylin Pharmaceuticals
Nov. 26, 2003
Biosite Announced a License Agreement with Agenix for D-dimer
Feb. 20, 2003
Biosite Announced a Multi-Year Collaborative Agreement with Neurocrine Biosciences
Feb. 10, 2003
Ciphergen Biosystems and Biosite Announced a Collaboration for Cardiovascular and Other Diseases
Dec. 20, 2002
Proteome Sciences Announces a Major Collaboration and Licensing Agreement in the Field of Stroke with Biosite
Aug. 15, 2002
Biosite Announces Collaboration Agreement With MedImmune
Mar.11, 2002
Biosite Announces Collaboration Agreement With AMGEN; Amgen to Access the Medarex/Biosite Trans-phage™ technologySM
Jan. 4, 2001
Medarex, Lilly and Biosite to Collaborate
Jun. 1, 2000
Biosite and Medarex, Inc. Combine Leading Antibody Technologies
Sep. 30, 1999
Biosite Initiates Stroke Program Through Biosite Discovery
|